Abstracts Archive - Page 70 of 2425 - ACR Meeting Abstracts

Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0095 • ACR Convergence 2024
Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Minjung Kim¹, Cecilia Stumpf², Hadijat Makinde¹, Mohammad Khan¹, Vanessa Rodriguez², Tyler Therron², Jeremy Tilstra³, Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³University of Pittsburgh, Pittsburgh, PA, ⁴Northwestern University, Skokie, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
Abstract Number: 0065 • ACR Convergence 2024
Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis
Neela Fatemeh Moadab¹, Tal Gazitt², Rayan Najjar¹, Ethan Le¹, J Lee Nelson³, Vijay Joshua⁴, Keith Elkon¹, Caroline Grönwall⁴ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²Carmel Hospital, Haifa, Israel, ³University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) are diagnostic for rheumatoid arthritis (RA). The antigens recognized by these autoantibodies are produced by protein arginine deiminases (PADs), particularly…
Abstract Number: 0077 • ACR Convergence 2024
Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45
Fatma Zohra Yasmina Heddi¹, Zahira Lamri², kheireddine khelif², Amina Benammar² and wafa Zahdour², ¹Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Oran, Algeria, ²Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Algeria
Background/Purpose: The onset of axial spondyloarthritis (axSpA), as defined by the Assessment of SpondyloArthritis International Society (ASAS) criteria is unusual after the age of 45…
Abstract Number: 0022 • ACR Convergence 2024
Transcriptomic Characterization of Knee Capsule Fibroblasts and Mesenchymal Stromal Cells Reveals an Association Between Flexion Contracture and Alterations in Immune Pathways in People with End-stage OA
Odette Laneuville¹, Daniel Stratis¹, Robert Feibel², Guy Trudel³ and T Mark Campbell⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Bruyère Research Institute, Ottawa, ON, Canada
Background/Purpose: Over 10% of adults have symptomatic knee OA but no disease-modifying interventions exist. A flexion contracture (loss of extension; FC) presents in 1/3 of…
Abstract Number: 0104 • ACR Convergence 2024
Proteomic Analysis Identifies Neutrophil Defensin 1 as a Biological Marker for Antiphospholipid Syndrome
Yuebing Wang¹ and chun Li², ¹Department of Rheumatology and Immunology, Peking University People’s Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing, China, Beijing, China, ²Peking University People's Hospital, Beijing, China
Background/Purpose: Antiphospholipid syndrome (APS) is a distinct type of thrombophilia caused by autoantibodies, characterized by repeated thrombosis and complications during pregnancy. This study aimed to…
Abstract Number: 0094 • ACR Convergence 2024
Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice
Thomas Winans¹, Xiaojing Wang², Joshua Lewis², Jessica Nolan¹, Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, ²SUNY Upstate Medical University, Syracuse, NY, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY
Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
Abstract Number: 0083 • ACR Convergence 2024
Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice
Mariia Korshko¹, Shaghayegh Foroozan Boroojeni² and Nigil Haroon³, ¹University Health Network, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0105 • ACR Convergence 2024
Novel Autoantibodies Identified in the Antiphospholipid Syndrome
Shikai Hu¹, Yangzhong Zhou¹, Menghua Cai¹, Mengtao Li² and JIULIANG ZHAO¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, recurrent pregnancy morbidity, or non-thrombotic manifestations in the…
Abstract Number: 0044 • ACR Convergence 2024
Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes
Cankut Cubuk¹, Rachel Lau¹, Vinothini Rajeeve², Pedro Cutillas², Rebecca Hands¹, Liliane Fossati-Jimack¹, Anna Surace¹, Alessandra Nerviani¹, Felice Rivellese¹, Myles Lewis³ and Costantino Pitzalis⁴, and the R4RA Collaborative Group, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ²Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴QMUL, Bromley Kent, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an incurable autoimmune disease where response to therapy is heterogenous. Clinically indistinguishable RA patients can be classified histo-pathologically into three…
Abstract Number: 0113 • ACR Convergence 2024
Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Alexander Pine¹, Vittorio Pengo², Savino Sciascia³, Nina Kello⁴, Rosario Lopez Pedrera⁵, H Michael Belmont⁶, David Branch⁷, Laura Andreoli⁸, Michelle Petri⁹, Ricard Cervera¹⁰, Jason Knight¹¹, Pierluigi Meroni¹², Hannah Cohen¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Alfred Lee¹⁶, Doruk Erkan¹⁷ and Anish Sharda¹⁶, ¹Yale School of Medicine/VA Connecticut, West Haven, CT, ²Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ³University of Turin, Torino, Turin, Italy, ⁴Northwell Health, Brooklyn, NY, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶NYU School of Medicine, New York, NY, ⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁸University of Brescia, Brescia, Italy, ⁹Johns Hopkins University School of Medicine, Timonium, MD, ¹⁰Hospital Clinic de Barcelona, Barcelona, Spain, ¹¹University of Michigan, Ann Arbor, MI, ¹²IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Yale School of Medicine, New Haven, CT, ¹⁷Hospital for Special Surgery, New York, NY
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thromboembolic and obstetric morbidity arising via a model of immunothrombosis. Patients may present with thrombotic (tAPS),…
Abstract Number: 0112 • ACR Convergence 2024
Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts
Arne Vandevelde¹, Pierluigi Meroni², Hannah Cohen³, Danieli Andrade⁴, Olga Amengual⁵, TATSUYA ATSUMI⁵, Angela Tincani⁶, H Michael Belmont⁷, Maria Borghi⁸, David Branch⁹, Ricard Cervera¹⁰, Guilherme Ramires de Jesús¹¹, Paul Fortin¹², Jean-Christophe Gris¹³, Claudia Grossi⁸, Jason Knight¹⁴, Gary W. Moore¹⁵, Jacek Musiał¹⁶, Michelle Petri¹⁷, Esther Rodriguez-Almaraz¹⁸, Diana Paredes-Ruiz¹⁹, Robert Roubey²⁰, Anne Tebo²¹, Maria Tektonidou²², Denis WAHL²³, Stéphane Zuily²³, Rohan Willis²⁴, Vittorio Pengo²⁵, Maria Laura Bertolaccini²⁶, Doruk Erkan²⁷ and Katrien Devreese¹, ¹Department of Diagnostic Sciences, Ghent University and Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium, ²IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴University of São Paulo, São Paulo, SP, Brazil, ⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁶ASST Spedali Civili-University of Brescia, Brescia, Italy, ⁷NYU School of Medicine, New York, NY, ⁸Immunorheumatology research laboratory, IRCCS Istituto Auxologico, Milan, Italy, ⁹University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁰Hospital Clinic de Barcelona, Barcelona, Spain, ¹¹Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹³Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France and Department of Hematology, Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France and UMR UA11 INSERM IDESP - Montpellier University, France and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, United Kingdom and Department of Natural Sciences, Middlesex University, London, United Kingdom, ¹⁶Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland, ¹⁷Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁹Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ²⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ²²National and Kapodistrian University of Athens, Athens, Greece, ²³Lorraine University, Nancy, France, ²⁴University of Texas Medical Branch, Galveston, TX, ²⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ²⁶King's College London, London, United Kingdom, ²⁷Hospital for Special Surgery, New York, NY
Background/Purpose: Correlation of numerical values between the low, moderate, and high (L, M,H) levels of enzyme-linked immunosorbent assay (ELISA) and non-ELISA platforms for anticardiolipin antibody…
Abstract Number: 0084 • ACR Convergence 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Xi Li, bing Li, Jun Yao, bin zhang, zhongyuan zhu, yang Qiu and haiqing Hua, Duality Biologics Ltd, Shanghai, China (People's Republic)
Background/Purpose: BDCA2 (blood dendritic cell antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), whose over-production of type I interferon (IFN-I) is crucial in…
Abstract Number: 0111 • ACR Convergence 2024
Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
Polona Zigon¹, Nika Bostič¹, Ziga Rotar², Ales Ambrozic³, Elizabeta Blokar³, Manca ogrič¹ and Sasa Cucnik¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana
Background/Purpose: Recently published 2023 ACR/EULAR APS classification criteria emphasize delineating moderate/high anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. The new criteria specify the use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].